Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

China Inc. Shines In Latest Batch Of Approvals

Global-First PD-1 Nod For Nasopharyngeal Cancer In China

Apr 27 2021

• By Brian Yang

China New Drug Approvals 2020 — FLURRY OF DOMESTIC APPROVALS FOR CHINESE FIRMS • Source: Alamy

Related Content

PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review

Apr 24 2021

Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing

Jan 25 2021

David Now Goliath? Made In China PD-1s Sought After By Multinationals

Mar 03 2021

Oncology, Rare Disease Drugs Dominate New China Approvals

Dec 09 2020

Related Companies

RemeGen Ltd.

Blueprint Medicines Corporation

Shanghai Junshi Biosciences Co., Ltd.

Takeda Pharmaceutical Co. Ltd.

AstraZeneca PLC

Coherus Oncology, Inc.

Additional Topics

China Asia Pacific Approvals Regulation Cancer BioPharmaceutical

More from China

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window